In DepthInfectious Disease

As Ebola epidemic draws to a close, a thin scientific harvest

Science  01 Jan 2016:
Vol. 351, Issue 6268, pp. 12-13
DOI: 10.1126/science.351.6268.12

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Summary

As the Ebola epidemic exploded in the summer of 2014, a frenzied effort began to test vaccines and drugs in Liberia, Sierra Leone, and Guinea. But so far, results from just one clinical trial have appeared in a peer-reviewed journal; it showed Merck's Ebola to be remarkably successful. A dozen other trials have yet to be published. Many didn't deliver a clear answer because they failed to enroll the planned number of participants. Others did recruit enough patients but didn't use a randomized controlled trial design, which weakened results. Still others were halted early. One last hope for an uplifting result remains: an ongoing study of ZMapp, a promising antibody cocktail.